3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Squamous Cell Carcinoma of Head and Neck
19
Breast Neoplasms
18
Lung Neoplasms
17
Colorectal Neoplasms
15
Neoplasms
12
Neoplasm Metastasis
12
Head and Neck Neoplasms
12
Ovarian Neoplasms
11
Small Cell Lung Carcinoma
9
Recurrence
9
Sarcoma
8
Pancreatic Neoplasms
8
Prostatic Neoplasms
7
Advanced Solid Tumors
7
Urinary Bladder Neoplasms
6
Triple Negative Breast Neoplasms
6
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Uterine Cervical Neoplasms
5
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
5
Biliary Tract Neoplasms
5
Mesothelioma, Malignant
4
Lymphoma, Follicular
4
Lymphoma
4
Fallopian Tube Neoplasms
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Interventions
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
pembrolizumab
1
olaparib
1
durvalumab
1
capivasertib
1
Vinorelbine
1
Ramucirumab
1
Pemetrexed
1
Paclitaxel
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-small Cell Lung Cancer Metastatic
×
durvalumab
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled